The door is open to change the United States platform of healthcare for Cardiovascular Disease (CVD) in terms of maintaining arterial wellness. Accomplishments in this arena of healthcare have been phenomenal. But CV healthcare was established on a platform that treats end-stage disease. At the time, existent technology and knowledge could only manage evident arterial disease. The financial and intellectual commitment in this area of healthcare have resulted in astonishing accomplishments such as coronary bypass grafting, angioplasty, etc. The consequence has been dramatic reduction in CV mortality. Unfortunately, the incidence of end-stage arterial disease has not been significantly impacted. In addition, the price tag has been substantial in terms of financial resources and quality of life. One can avoid fiscal insolvency and deteriorating quality of life by shifting to a platform that prevents arterial disease or, at minimum, treats it before it is evident. Being in an era of technology sufficient to identify subclinical arterial disease and knowledge necessary to halt atherosclerosis. Additionally, numerous health issues are known to produce inflammation of the arteries, which is causal of atherosclerosis. Each can be managed effectively to extinguish the inflammation. When this is accomplished the disease will halt, which significantly mitigates risk for an acute obstructive cardiovascular event. CV healthcare can now enter a new era of maintaining arterial wellness. One must seize this opportunity for fiscal and humanitarian reasons.